SIMandCURE Revenue and Competitors

Founded in 2014 and located in the vibrant Medtech ecosystem in Montpellier, France, Sim&Cure is a digital start-up focused on improving neurovascular treatments of cerebral aneurysm with a proprietary software suite (Class IIa medical device with CE mark and FDA 510k cleared) that has already been used to treat more than 5,000 patients in 350 hospitals. Sim&Cure has won the prestigious i-Lab national contest twice in 2014 and 2015 and i-Nov in 2020, The start-up is backed by the Seed Fund IT-Translation and Elaia Partners Sim&Cure has established scientific and clinical collaborations with leading laboratories and hospitals around the world. Sim&Cure opened a subsidiary in US (NY) in July 2019. The company employs 27 people and anticipates a phase of strong growth. The medical device software Sim&Size allows physicians to define their therapeutic strategy thanks to the different modules: - FDsize for Flowdiverters - IDisze for Intrasaccular devices - STsize for Supporting stents - FCsize for Framing coils. Since 2020, Sim&Cure also provides a training platform Sim&Train based on 3D printing technology and an educational version of Sim&Size. The Sim&Cure goal is to always develop more products to secure neurovascular treatment.